

Study Number: C13115-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA48: Summary of Tissue Concentration

Test Compound: 3-(2H-Benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid, octyl ester

CAS Number: 84268-23-5

Date Report Requested: 10/10/2023

Time Report Requested: 16:23:03

Lab: Battelle

Study Number:

C13115-01

Study Sex:

Male

PWG Approval Date:

See web page for date of PWG Approval

Version:

v1.5.3

Stat Version:

2023.02.27S

Study Number: C13115-01**Test Type:** TOX**Route:** Oral Gavage**Species/Strain:** Rat/Harlan Sprague Dawley**PA48: Summary of Tissue Concentration****Test Compound:** 3-(2H-Benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid, octyl ester**CAS Number:** 84268-23-5**Date Report Requested:** 10/10/2023**Time Report Requested:** 16:23:03**Lab:** Battelle

		Male							
Phase	Dose (mg/kg)	0	30	100			300		
SD 14	Plasma Free 3-(2H-benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid, octyl ester Concentration (ng/ml)	BD	BD	1.15 ± 0.300 (5)			7.87 ± 1.96 (5)		
SD 14	Plasma Free 3-(2H-benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid, octyl ester Concentration (nM)	BD	BD	2.55 ± 0.664 (5)			17.4 ± 4.33 (5)		
SD 14	Plasma Total 3-(2H-benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid, octyl ester Concentration (ng/ml)	0.0836 ± 0.0251 (4) **	68.9 ± 30.5 (5) *	201	± 38.4	(5) **	2510	± 1180	(5) **
SD 14	Plasma Total 3-(2H-benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid, octyl ester Concentration (nM)	0.185 ± 0.0556 (4) **	153 ± 67.5 (5) *	444	± 85.0	(5) **	5560	± 2610	(5) **

Study Number: C13115-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA48: Summary of Tissue Concentration

Test Compound: 3-(2H-Benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid, octyl ester

CAS Number: 84268-23-5

Date Report Requested: 10/10/2023

Time Report Requested: 16:23:03

Lab: Battelle

Male			
Phase	Dose (mg/kg)	1000	
SD 14	Plasma Free 3-(2H-benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid, octyl ester Concentration (ng/ml)	767 ±	222 (4)
SD 14	Plasma Free 3-(2H-benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid, octyl ester Concentration (nM)	1700 ±	492 (4)
SD 14	Plasma Total 3-(2H-benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid, octyl ester Concentration (ng/ml)	184000 ±	50400 (4) **
SD 14	Plasma Total 3-(2H-benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid, octyl ester Concentration (nM)	407000 ±	112000 (4) **

Study Number: C13115-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA48: Summary of Tissue Concentration

Test Compound: 3-(2H-Benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid, octyl ester

CAS Number: 84268-23-5

Date Report Requested: 10/10/2023

Time Report Requested: 16:23:03

Lab: Battelle

LEGEND

Data are displayed as mean $\pm$ SEM (N) unless otherwise noted.

SD – Study Day

If over 20% of the animals in a group were above the limit of detection, then 1/2 the limit of detection value was substituted for values that were below the limit of detection.

BD - Group did not have over 20% of its values above the limit of detection.

When the control group did not have over 20% of its values above the limit of detection, no mean or standard error were calculated and no statistical analysis was done for the endpoint.

Statistical analysis was performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at $P \leq 0.05$

** Statistically significant at $P \leq 0.01$

Values adjusted for molar concentration were calculated by dividing the absolute measurement by the molecular weight of 451.6 g/mol

Decrease in N for Plasma Free 3-(2H-benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid, octyl ester and Plasma Total 3-(2H-benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid, octyl ester in the 1000 mg/kg group is due to one animal's value being excluded because it was an outlier.

Decrease in N for Plasma Total 3-(2H-benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid, octyl ester in the control group is due to one animal with no measurement available.

**** END OF REPORT ****